Qvanteq AG

Gegründet: Januar 2009

Novel stent technologies to address and overcome clinical shortcomings.

Qvanteq develops novel stent technologies to address and overcome the clinically adverse effects of today’s available coronary artery stents. A coronary stent is a small (metal) mesh tube which is being implanted into coronary arteries to prevent heart attacks.

Qvanteq is a CTI start-up company and a spin-off from the Swiss Federal Institute of Technology (ETH) Zurich. The company was founded in early 2009 and is held by private investors. Its Headquarter is located at Technopark in Zurich, Switzerland.

Milestones / News

	12.02.2013 Swiss coronary stent developer Qvanteq closes MCHF 4 B round
	27.04.2010 Seed capital round for Qvanteq
	08.09.2009 Qvanteq obtains venture kick first round 10 KCHF